ArticleBMC medical imaging2025
Habitat-derived radiomics analysis based on dual lesion for the prediction of microvascular invasion in bifocal hepatocellular carcinoma.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aims to predict microvascular invasion (MVI) in bifocal hepatocellular carcinoma (bHCC) by analyzing the habitat and radiomic features of the two tumor lesions, and further to establish a prediction model to estimate the prognosis of bHCC patients.
methods183 bHCC patients were enrolled, randomly dividing into a training cohort (n = 146) and a test cohort (n = 37) in an 8:2 ratio. Habitat analysis was performed in two tumors as a whole one to construct the habitat model. The radiomic features were further extracted from the habitat-derived subregions. The logistic regression was used to identify the clinicoradiological variables associated with MVI. The Clinical-Radiological-Habitat (CRH) model combined clinicoradiological and habitat features, while the comprehensive model further integrated habitat-derived radiomics for MVI prediction. Diagnostic performance was assessed using receiver operating characteristic curve analysis, and prognostic analysis was performed using the Kaplan-Meier curves.
resultsThe dual tumors in bHCC patients were analyzed as a whole tumor and divided into two habitats (habitat 1 and 2). The habitat model demonstrated AUCs of 0.817 and 0.700 for assessing MVI in the training and testing cohorts, respectively. The CRH model outperformed the habitat model with the AUCs of 0.837 and 0.766 in the training and testing cohorts. The comprehensive model combined habitat-derived radiomics features on arterial phase and T2-weighted imaging with CRH model and achieved excellent diagnostic performance with AUCs of 0.907 and 0.884 in the training and test cohorts, respectively. The model’s clinical relevance was further supported by calibration and decision curve analysis. Additionally, the model showed high predictive accuracy for survival outcomes in risk stratification.
conclusionThe H1 − AP+T2WI+CRH model hold promise as a non-invasive tool for predicting MVI and overall survival in bHCC patients, offering a valuable approach for preoperative risk assessment. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.